Teva Pharmaceutical Industries Debt to Equity Ratio 2006-2018 | TEVA

Current and historical debt to equity ratio values for Teva Pharmaceutical Industries (TEVA) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Teva Pharmaceutical Industries debt/equity for the three months ending September 30, 2018 was 1.75.
Teva Pharmaceutical Industries Debt/Equity Ratio Historical Data
Date Long Term Debt Shareholder's Equity Debt to Equity Ratio
2018-09-30 $26.82B $15.31B 1.75
2018-06-30 $28.97B $15.61B 1.86
2018-03-31 $29.45B $16.41B 1.80
2017-12-31 $28.83B $15.11B 1.91
2017-09-30 $31.97B $26.68B 1.20
2017-06-30 $33.81B $25.99B 1.30
2017-03-31 $32.69B $32.13B 1.02
2016-12-31 $32.52B $31.37B 1.04
2016-09-30 $33.18B $33.41B 0.99
2016-06-30 $8.04B $28.40B 0.28
2016-03-31 $8.62B $26.97B 0.32
2015-12-31 $8.36B $26.64B 0.31
2015-09-30 $9.52B $22.90B 0.42
2015-06-30 $9.50B $23.09B 0.41
2015-03-31 $9.39B $22.68B 0.41
2014-12-31 $8.57B $23.36B 0.37
2014-09-30 $8.82B $23.67B 0.37
2014-06-30 $9.12B $23.59B 0.39
2014-03-31 $10.24B $23.03B 0.45
2013-12-31 $10.39B $22.64B 0.46
2013-09-30 $10.06B $22.39B 0.45
2013-06-30 $9.93B $21.61B 0.46
2013-03-31 $9.94B $22.81B 0.44
2012-12-31 $11.71B $22.87B 0.51
2012-09-30 $12.69B $23.07B 0.55
2012-06-30 $12.63B $22.89B 0.55
2012-03-31 $10.16B $23.20B 0.44
2011-12-31 $10.24B $22.34B 0.46
2011-09-30 $4.37B $22.94B 0.19
2011-06-30 $3.92B $23.75B 0.17
2011-03-31 $4.88B $23.13B 0.21
2010-12-31 $4.11B $22.00B 0.19
2010-09-30 $4.74B $21.71B 0.22
2010-06-30 $5.07B $19.36B 0.26
2010-03-31 $3.46B $19.68B 0.18
2009-12-31 $4.31B $19.26B 0.22
2009-09-30 $4.30B $19.30B 0.22
2009-06-30 $4.72B $17.85B 0.26
2009-03-31 $5.06B $16.14B 0.31
2008-12-31 $5.54B $16.30B 0.34
2008-09-30 $3.92B $14.84B 0.26
2008-06-30 $3.32B $15.08B 0.22
2008-03-31 $3.35B $14.40B 0.23
2007-12-31 $3.35B $13.72B 0.24
2007-09-30 $3.36B $12.92B 0.26
2007-06-30 $3.98B $12.06B 0.33
2007-03-31 $4.01B $11.39B 0.35
2006-12-31 $4.59B $11.14B 0.41
2006-09-30 $4.67B $10.58B 0.44
2006-06-30 $4.59B $9.90B 0.46
2006-03-31 $4.60B $9.22B 0.50
2005-12-31 $1.77B $6.04B 0.29
2005-09-30 $1.62B $5.57B 0.29
2005-06-30 $1.72B $5.31B 0.32
2005-03-31 $1.73B $5.30B 0.33
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $18.751B $22.385B
TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $51.396B 8.82
Mylan (MYL) United Kingdom $15.624B 6.43
Bausch Health Cos (BHC) Canada $7.992B 5.78
Dr Reddy's Laboratories (RDY) India $6.105B 24.35
Supernus Pharmaceuticals (SUPN) United States $1.981B 18.77
Mallinckrodt Public Limited Company (MNK) United Kingdom $1.723B 2.87
Amphastar Pharmaceuticals (AMPH) United States $1.014B 110.00
Homology Medicines (FIXX) United States $0.986B 0.00
Assembly Biosciences (ASMB) United States $0.640B 0.00
Akorn (AKRX) United States $0.560B 0.00
CymaBay Therapeutics (CBAY) United States $0.520B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.367B 0.00
Voyager Therapeutics (VYGR) United States $0.359B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.268B 0.00
Sol-Gel Technologies (SLGL) Israel $0.116B 0.00
Teligent (TLGT) United States $0.088B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.081B 0.00
Aevi Genomic Medicine (GNMX) United States $0.076B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.055B 0.00
Acasti Pharma (ACST) Canada $0.051B 0.00
Evoke Pharma (EVOK) United States $0.044B 0.00
Agile Therapeutics (AGRX) United States $0.028B 0.00
China Pharma Holdings (CPHI) China $0.011B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.004B 0.00